AUSTIN, Texas, June 5, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9, 2017 at 1:00 p.m. Eastern time in Ballroom 1 at the Grand Hyatt hotel in New York.
Interested parties can access a live audio webcast on the Savara web site at www.savarapharma.com. An archived presentation will be available on the web site for 30 days.
About Savara
Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises Molgradex, a Phase 3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, AeroVanc, an inhaled vancomycin in preparation for Phase 3, and Aironite, an inhaled sodium nitrite solution in Phase 2 development. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, creating and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/savara-to-present-at-the-jefferies-2017-global-healthcare-conference-on-june-9th-300468347.html
SOURCE Savara Inc.
Savara Inc., Ioana C. Hone, (ir@savarapharma.com), (512) 961-1891
